CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Harbin%25252c%252520heilongjiang, China

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

    Phase

    3

    Span

    261 weeks

    Sponsor

    First Affiliated Hospital of Zhejiang University

    Harbin

    Recruiting

  • Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

    Phase

    3

    Span

    102 weeks

    Sponsor

    Beijing InnoCare Pharma Tech Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

    Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent. Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.

    Phase

    1

    Span

    160 weeks

    Sponsor

    Risen (Suzhou) Pharma Tech Co., Ltd.

    Harbin

    Recruiting

  • Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

    Phase

    1/2

    Span

    89 weeks

    Sponsor

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

    Phase

    2

    Span

    155 weeks

    Sponsor

    Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

    Phase

    2

    Span

    108 weeks

    Sponsor

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

    Primary objective: to evaluate the efficacy of RC148 injection as monotherapy or combination therapy in patients locally advanced or metastatic non-small cell lung cancer;

    Phase

    1

    Span

    125 weeks

    Sponsor

    RemeGen Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • Study on c-Met Targeted PET/CT Imaging in NSCLC

    In the study, NSCLC patients with different c-Met activation status (c-Met overexpression, MET exon 14 skipping mutation, MET amplification, MET wild type) confirmed by pathology or gene detection will receive 18F-TSPF PET/CT and 18F-FDG PET/CT respectively. The goal of the study is to evaluate specificity and accuracy of 18F-TSPF as a novel PET radiotracer to detect c-Met activation status and potentially identify c-Met-TKIs benefited NSCLC patients.

    Phase

    N/A

    Span

    88 weeks

    Sponsor

    Xilin Sun

    Harbin, Heilongjiang

    Recruiting

    Healthy Volunteers

  • A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

    Phase

    3

    Span

    146 weeks

    Sponsor

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

  • Clinical Studies for the Treatment of Advanced Solid Tumors

    Phase

    1/2

    Span

    78 weeks

    Sponsor

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

    Harbin, Heilongjiang

    Recruiting

1-10 of 427
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information